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Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and epidermal growth factor receptor (EGFR) family
signaling are drivers of tumorigenesis in pancreatic ductal adenocarcinoma (PDAC). Previous studies have
demonstrated that combinatorial treatment of PDAC xenografts with the mitogen-activated protein kinase–
extracellular-signal-regulated kinase (ERK) kinase1/2 (MEK1/2) inhibitor trametinib and the dual EGFR/human
epidermal growth factor receptor 2 (HER2) inhibitor lapatinib provided more effective inhibition than either
treatment alone. In this study, we have used the therapeutic antibodies, panitumumab (specific for EGFR) and
trastuzumab (specific for HER2), to probe the role of EGFR and HER2 signaling in the proliferation of patient-
derived xenograft (PDX) tumors. We show that dual anti-EGFR and anti-HER2 therapy significantly augmented the
growth inhibitory effects of the MEK1/2 inhibitor trametinib in three different PDX tumors. While significant growth
inhibition was observed in both KRAS mutant xenograft groups receiving trametinib and dual antibody therapy
(tumors 366 and 608), tumor regression was observed in the KRAS wild-type xenografts (tumor 738) treated in the
same manner. Dual antibody therapy in conjunction with trametinib was equally or more effective at inhibiting
tumor growth and with lower apparent toxicity than trametinib plus lapatinib. Together, these studies provide
further support for a role for EGFR and HER2 in pancreatic cancer proliferation and underscore the importance of
therapeutic intervention in both the KRAS–rapidly accelerated fibrosarcoma kinase (RAF)–MEK–ERK and EGFR-
HER2 pathways to achieve maximal therapeutic efficacy in patients.
Neoplasia (2014) 16, 562–571Introduction
Pancreatic cancer is the 10th most common US cancer and the 4th
leading cause of cancer death in the United States. The 5-year survival
from this disease has barely improved from 2% to 6% in the last
40 years [1]. These poor outcomes coupled with a projected increasein disease incidence of 55% in the next 20 years highlight the pressing
need for improved systemic therapies for this disease [2].
Central to the failure of existing treatment strategies is the marked
genetic heterogeneity and resultant molecular signaling complexity
observed in pancreatic cancers [3–5]. Despite this diversity, aE-mail: twb7f@virginia.edu
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majority of pancreatic ductal epithelial cells during their malignant
transformation to adenocarcinoma. Activating mutations of the
Kirsten rat sarcoma viral oncogene homolog (KRAS) have been reported
in 75% to 95% of pancreatic ductal adenocarcinomas (PDAC), and
the importance of this oncogene in pancreatic tumorigenesis has been
demonstrated in genetically engineered mouse models [6–11].
Developing strategies to target RAS pathway signaling at the
preclinical and clinical levels has been emphasized as a high priority
in pancreatic cancer research [12]. Small molecule inhibitors of both
rapidly accelerated fibrosarcoma kinase (RAF) and mitogen-activated
protein kinase (MAPK)–extracellular-signal-regulated (ERK)
kinase1/2 (MEK1/2) within the RAS-RAF-MEK-ERK signaling
cascade are in clinical development with promising early results in
mutant RAS/RAF-driven tumors [13,14].
The epidermal growth factor receptor (EGFR) families have also
been identified as promising targets for PDAC treatment. The
observation that 40% to 70% of PDAC tumors overexpress EGFR led
to the testing and US Food and Drug Administration (FDA) approval
of erlotinib, an EGFR-specific tyrosine kinase inhibitor, in combina-
tion with gemcitabine for the treatment of patients with advanced
disease [15,16]. Additionally, human epidermal growth factor receptor
2 (HER2) has been identified as overexpressed in approximately 20%
of PDAC tumors [17]. Its overexpression has been associated with
worse patient outcomes, and anti-HER2 therapy has exhibited
therapeutic synergism with anti-EGFR agents in pancreatic xenografts
expressing moderate and even low levels of HER2 [18–20].
Despite promising early results with RAS pathway inhibitors and anti-
EGFR family therapy, the genetic heterogeneity, signaling redundancy,
and plasticity of pancreatic tumor cells suggest that monotherapy or
single pathway treatment strategies are unlikely to result in significant
and durable responses [5]. Importantly, preclinical studies evaluating
combination therapy with EGFR and RAS pathway inhibitors in
pancreatic cancer xenografts have shown promising results [21–23].
To develop and test rational approaches to therapy for PDAC, we
have established a patient-derived xenograft (PDX) model of
pancreatic cancer with orthotopic implantation of tumors into
immunocompromised mice. Genetic and molecular profiling of the
initial 15 PDXs in this tumor bank revealed a high frequency of
tumors with KRAS mutations and activated EGFR and a smaller
cohort with activated HER2 [24]. In this preclinical model, we
evaluated combination therapy with trametinib (GSK1120212), a
selective allosteric inhibitor of MEK1/2 [16,25,26], plus lapatinib, an
inhibitor of both EGFR and HER2 receptor tyrosine kinase (RTK)
activity [27–29]. We reported that trametinib-mediated tumor
growth inhibition was significantly enhanced by concomitant
lapatinib therapy in four of five patient-derived tumors assessed [23].
While this combination therapy was highly efficacious and
considered for a clinical trial, there were concerns about potential
patient toxicity as a recent phase I/Ib study evaluating trametinib in
combination with erlotinib in patients with non–small cell lung and
pancreatic cancers reported treatment-limiting gastrointestinal toxic-
ity [30]. We therefore sought to identify alternate agents targeting
EGFR and HER2 to use in combination with trametinib.
In this study, we have used two well-studied therapeutic
antibodies, panitumumab (specific for EGFR) and trastuzumab
(specific for HER2), to probe the role of EGFR and HER2 signaling
in the proliferation of PDX tumors bearing mutant and wild-type
KRAS alleles. We show that dual anti-EGFR and anti-HER2 therapysignificantly augmented the growth inhibitory effects of the MEK1/2
inhibitor trametinib in different PDX tumors. Particularly notewor-
thy was the observation that two different tumors bearing wild-type
KRAS alleles were particularly sensitive to trametinib plus dual
antibody therapy exhibiting significant tumor regression. In vitro and
in vivo studies confirmed that treatment with panitumumab or
trastuzumab effectively inhibited the epidermal growth factor (EGF)–
dependent autophosphorylation of EGFR and HER2, respectively.
These studies using PDX tumors support the role for EGFR and
HER2 in pancreatic cancer proliferation and underscore the
importance of therapeutic intervention in both the KRAS-RAF-
MEK-ERK and EGFR-HER2 pathways to achieve maximal
therapeutic efficacy in vivo.
Materials and Methods
Orthotopic PDXs and Cell Lines
PDAC cell line and tumor samples MAD 08-608, 08-738, 09-366,
and 10-215 (T608, T738, T366, and T215, respectively) were
generated from fresh human tumor specimens collected with the
approval of the University of Virginia’s Institutional Review Board and
Animal Care and Use Committee following informed consent from
each patient as previously described [23,31]. Six- to 8-week-old male
athymic nude mice were used for all in vivo experiments. For in vitro
experiments, cells were maintained in Roswell Park Memorial Institute
1640 medium containing 10% FBS and 1% penicillin/streptomycin
and cultured in a humidified (37 °C, 5% CO2) incubator. Fresh cell
aliquots were thawed, propagated, and used for experiments every
6 months. Cell lines were authenticated in 2010 by the University of
Virginia Biomedical Research Facility as previously described [23].
MEK1/2 Inhibitor, EGFR/HER2 Inhibitor, and Antibodies
Trametinib (GSK1120212), a selective allosteric inhibitor ofMEK1/
2 [16,25,26], and lapatinib, a dual tyrosine kinase inhibitor of EGFR
and HER2, were kindly provided by GlaxoSmithKline (Brentford,
United Kingdom). Panitumumab (Amgen, Thousand Oaks, CA) is a
fully humanized, anti-EGFR monoclonal antibody that is FDA
approved for the treatment of metastatic colorectal cancer with disease
progression on standard therapy [32]. Trastuzumab (Genentech, San
Francisco, CA) is a humanized anti-HER2 monoclonal antibody that is
FDA approved for the treatment of HER2 overexpressing breast cancer
[33]. Pertuzumab (Roche, Basel, Switzerland) is a humanized anti-
HER2 monoclonal antibody that inhibits HER2 dimerization and has
improved survival for patients with metastatic breast cancer in
combination with trastuzumab and docetaxel [34]. The University of
Virginia Medical Center’s Investigational Drugs Pharmacy kindly
provided panitumumab, trastuzumab, and pertuzumab.
In Vitro Molecular Response Assays
To assess the molecular responses to EGF stimulation, tumor 366
cells were plated and allowed to adhere overnight in a six-well plate in
regular culture conditions. Cells were then starved in serum-free
media for 4 hours before the addition of drug combinations
(panitumumab, 5 μg/ml; trastuzumab, 20 μg/ml; trametinib,
10 nM) or phosphate-buffered saline (PBS)/DMSO control. One
cohort of cells remained in 10% FBS-containing media as a control
population. After 1 hour of drug treatment, one cohort of cells was
stimulated with 100 ng/ml human EGF or PBS control. Thirty
minutes later, samples were lysed and Western blot performed with
previously described techniques and antibodies [23].
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Tumor pieces (~50 mg) were orthotopically implanted onto the
pancreata of 6- to 8-week-old male athymic nude mice. Tumors were
allowed to grow for 3 to 4 weeks to a volume of 100 to 500 mm3 as
assessed by volumetric magnetic resonance imaging (MRI), at which
point drug treatment commenced. Mice were treated with either
vehicle (0.5% hydroxypropyl methylcellulose in 0.1% Tween 80) or a
combination of trametinib, panitumumab, and/or trastuzumab as
indicated in the text and figures. Dosing was given as follows:
trametinib (0.3 mg/kg orally, once daily), panitumumab (200 μg,
intraperitoneal injection, twice weekly), trastuzumab (500 μg,
intraperitoneal injection, twice weekly), pertuzumab (200 μg,
intraperitoneal injection, twice weekly). In all experiments, volumet-
ric MRI was used to assess changes in tumor volume at 7-day intervals
while on drug treatment, as previously described [23]. Mice were then
sacrificed, tumors were completely excised, weighed, and measured by
calipers, and mice were examined for the presence of metastatic
disease. To determine the therapeutic efficacy of drug combinations,
an MRI was obtained just before the start of treatment to establish an
index tumor volume for each mouse. Subsequent interval MRI
studies were used to assess the change in tumor volume while on
treatment. The interval tumor volumes were divided by the index
tumor volume to calculate the relative change in tumor volume (fold
change) for each tumor. Linear regression was used to model a line of
best fit for the tumor fold change data plotted relative to time. The
slope of that line of best fit served as an estimate of the tumor growth
rate for each treatment group expressed as the fold change per week
on treatment. Upon completion of the experiment, pieces of tumor
were placed in Allprotect (Qiagen, Valencia, CA), snap-frozen in
liquid nitrogen, or fixed in formalin for histologic analysis.
Phospho-RTK and Phospho-MAPK Array Analyses
The activation status of 42 RTKs and 26 protein kinases including
9 MAPKs was assessed using the Proteome Profiler human phospho-
RTK (pRTK) array kit and human phospho-MAPK array kit (R&D
Systems, Minneapolis, MN), as previously described [23].
Statistical Analysis and Image Acquisition
The tumor volume of individual mice during treatment was
divided by starting volume to calculate relative change in tumor
volume, and linear regression was used to model tumor growth rate.
Student’s t test was used to compare continuous variables. All group
comparisons were unpaired. Continuous variables were expressed as
means ± SEM. All P values reported are two-tailed, and statistical
significance was indicated by P values of b .05. GraphPad Prism
(Version 5.0b) software (La Jolla, CA) was used for all statistical
analyses. Image acquisition and analysis for all Western blot data were
performed using the Odyssey Infrared Imaging System (LI-COR,
Lincoln, NE) and Image Studio V2.1 software (LI-COR) and for all
array data using a Bio-Rad GS-800 calibrated densitometer (Bio-Rad,
Hercules, CA) and ImageQuant TL 2005 (GE Healthcare, Piscat-
away, NJ) software. Blots and array images were cropped and spliced
for clarity and ease of comparison using Adobe Photoshop CS4
(Adobe, San Jose, CA).
Results
Genetic and Molecular Profiles of PDX Cells and Tumors
We have previously described the results of the genetic and
molecular profiling of 15 PDX tumors [24]. For the present study, weselected a cohort of four PDX tumors for which key genetic and
molecular characteristics are summarized in Table 1. Two of four
tumors (T366 and T608) harbor KRAS mutations (codon 12) and
were derived from liver metastases. The KRAS wild-type tumors
under study (T738 and T215) were derived from a primary
pancreatic tumor. Phospho-array analysis demonstrated that T608
and T215 exhibited high levels of activated phospho-EGFR (pEGFR)
and phospho-HER2 (pHER2) receptors, T366 exhibited readily
detectable pEGFR and low-level pHER2, and T738 showed the
lowest levels of both pEGFR and pHER2 [24]. No detectable
pHER3 or pHER4 signals were observed for any of the tumors
under study.
Panitumumab and Trastuzumab Inhibit the EGF-Dependent
Activation of EGFR and HER2 and Blunt the Feedback
Activation of AKT by Trametinib
To confirm the target specificity for panitumumab and trastuzu-
mab and their respective inhibition of receptor-mediated signaling,
we compared the relative pEGFR and pHER2 levels in 366 cells
following stimulation with EGF for 30 minutes (Figures 1 and W1).
Cells exposed to panitumumab alone or in combination with
trastuzumab showed a significant reduction in ligand-activated
pEGFR relative to the no antibody control (Figure 1, left panel).
Trametinib therapy alone produced no significant change in pEGFR,
while trastuzumab alone or in combination with trametinib produced
a statistically significant increase in relative pEGFR indicating that
anti-HER2 therapy absent anti-EGFR therapy promoted EGFR
phosphorylation. Cells exposed to either panitumumab or trastuzu-
mab in any combination elicited a reduction in pHER2 relative to no
antibody treatment control. The greatest decrease in pHER2 was seen
with dual antibody–treated cells (Figure 1, right panel). We speculate
that anti-EGFR therapy likely inhibits the phosphorylation of EGFR-
HER2 heterodimers and subsequent EGF-dependent HER2 signal-
ing. Interestingly, trametinib therapy alone produced a marked
increase in pHER2 consistent with a MEK-ERK–mediated feedback
activation of EGFR/HER2 (see below).
Next, we assessed changes in intracellular MAPK signaling in
extracts from EGF-stimulated cells pretreated with panitumumab,
trastuzumab, or combination treatment (Figure 2). In the 366 KRAS
mutant cell line, addition of EGF to serum-starved cells results in a
50% increase in pERK (as measured by the ratio of pERK/ERK).
Addition of panitumumab, trastuzumab, or the combination of
antibodies had only modest effects on basal or EGF-dependent
phosphorylation of pERK (Figure 2). As anticipated, trametinib
treatment markedly reduced pERK in both starved and EGF-
stimulated conditions. Addition of either antibody or both antibodies
to trametinib treatment effectively blocked the EGF-dependent
activation of pERK levels. Interestingly, we observed that in the
presence of trametinib, EGF stimulation produced an increase in
pAKT (pS473). This trametinib-dependent compensatory response
was blunted with the concomitant addition of either panitumumab or
combination antibody treatment consistent with the feedback
activation of the EGFR/HER2 pathway.In Vivo Response to Anti-EGFR, Anti-HER2, and MEK1/2
Inhibitor Therapy
To determine if the inhibitory antibodies, panitumumab and
trastuzumab, augment the trametinib-dependent inhibition of tumor
growth in vivo, serial MRI (sample images are shown in Figure 3, B,
Table 1. Characteristics of PDX Tumors and Cells
Tumor Primary or Metastatic Differentiation* Stromal Content Genetic Alterations † Relative Activation ‡
KRAS TP53 p16 SMAD4 pEGFR pHER2
366 Metastatic Poor Low mut mut wt mut High Low
608 Metastatic Well-Mod Low mut mut wt mut High High
738 Primary Poor High wt mut wt mut Low Low
215 Metastatic Poor High wt wt wt wt High High
* Poor, marked cellular atypia, solid single-cell growth; Well-Mod, mild to moderate cytologic atypia, gland forming.
† mut, mutant; wt, wild type.
‡ Phosphorylation state relative to background on R&D Systems pRTK array; Low, 1 to 2× background; High, N3× background.
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orthotopically implanted PDX tumors. To assess the extent to which
blockade of EGFR and HER2 augmented the inhibition of tumor
growth by trametinib, mice bearing PDX tumors were initially treated
with trametinib, panitumumab, or combination trametinib plus
panitumumab for 2 to 4 weeks (Figures 3 andW2). During this initial
treatment regimen, treatment with either trametinib or panitumumab
reduced tumor volume (Figure W2) and the rate of tumor growth
(Figure 3, hatched bars vs black bar) in all three PDX tumors. In the
KRAS mutant tumors 366 and 608, the addition of panitumumab to
trametinib therapy enhanced the inhibition of tumor growth. In
T738, both trametinib and panitumumab treatment yielded effective
inhibition of tumor growth with the addition of panitumumab to
trametinib yielding no additional inhibition.
To determine whether addition of the HER2 inhibitory antibody
trastuzumab would augment the effects of panitumumab, in the
initial treatment groups (trametinib plus panitumumab and
panitumumab alone), mice were “rolled on” to therapy with0.0
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Figure 1. Antibody-mediated inhibition of EGFR and HER2 in respons
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*P b .05. Figure W1 shows the complete array images.trastuzumab for an additional 2 weeks of therapy (Figures 3, A, C,
and E, open bars, and W2). For T366, the addition of trastuzumab
had no impact on the growth rate of tumors treated with trametinib
plus panitumumab (Figure 3A). In contrast, tumors 608 and 738
showed statistically significant decreases in growth rate with the
addition of anti-HER2 therapy to trametinib plus panitumumab
therapy (Figure 3, C and E). In a second KRAS wild-type tumor,
T215, addition of panitumumab and trastuzumab to trametinib
therapy again yielded significant inhibition of tumor growth (Figure
W2). These findings indicated that dual antibody therapy may prove
more efficacious in some PDX tumors, particularly with tumors with
higher levels of HER2 expression or with wild-type KRAS expression.
Triple Therapy Is as Effective as Trametinib plus
Lapatinib Treatment
To directly compare the efficacy and tolerability of triple therapy
versus trametinib plus lapatinib therapy as described previously [23],
mice bearing established T608 and T738 xenografts were randomizedEGFR
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Figure 2. ERK and AKT signaling in a PDX-derived tumor cell line. Western blot depicting the in vitro response of tumor 366 cells following
90 minutes of drug treatmentwith DMSO, panitumumab (5 μg/ml), trastuzumab (20 μg/ml), trametinib (10 nM), or the indicated combination
therapy (+ indicates drug present and− indicates drug absent) under EGF-stimulated or starved conditions. Starved cells weremaintained in
serum-freemedia for 4 hours before drug therapy and then given PBS after 60 minutes of drug exposure; EGF-stimulated cells (EGF+) were
starved for 4 hours before drug therapy and then exposed to 100 ng/ml of human EGF after 60 minutes of drug exposure. Lysates prepared
fromcells exposed to each indicated treatment groupwereblotted for pEGFR (Y1068), pERK1/2 (T202/204), ERK, pAKT (S473), AKT, andRAN.
The pERK/ERK and pAKT/AKT ratios are presented to permit quantitative comparisons between groups. Vertical bars denote the alignment of
different regions of the sameblot. All samples in two separate gelswere obtained fromone experiment and the samecontrolwas includedon
both gels. Image acquisition and analysis were performed using the Odyssey Infrared Imaging System and Image Studio V2.1 software.
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panitumumab/trastuzumab treatment for 4 weeks (Figures 4 and
W3). Whereas both tumor xenografts demonstrated significant
growth inhibition with the trametinib/lapatinib or trametinib/
antibody treatment regimen, T738 exhibited a pronounced and
durable tumor regression (Figures 4, A and B, and W3, A and C).
Mean tumor volume in T738 triple therapy–treated mice decreased by
75% without evidence of outgrowth while on therapy. In contrast,
trametinib plus lapatinib–treated tumors demonstrated tumor
outgrowth after 2 to 3 weeks of treatment despite an initial tumor
regression (T738) or cytostatic response (T608).
The tolerability of each regimen was assessed by comparing the
percent weight change of mice from each treatment group while on
therapy (Figure W3, B and D). We observed that for T608
trametinib plus lapatinib–treated mice lost a significantly higher
percentage of their body weight during treatment than triple therapy–
treated mice after 2 and 3 weeks of drug exposure. A similar trend was
observed early for T738 although significance was not achieved as
toxicity to trametinib plus lapatinib was much less compared to
T608. Collectively, these findings indicate that triple therapy is as or
more effective than trametinib plus lapatinib therapy but appears to
be less toxic.
Given the effectiveness of panitumumab + trastuzumab in
combination with trametinib in tumors 608 and 738, we tested the
activity of the HER2 dimerization inhibitor pertuzumab. Mice with
established T608 and T738 xenografts were treated with trametinib
in combination with pertuzumab for 4 weeks as above. As seen in
Figure 4, pertuzumab in combination with trametinib significantly
inhibited tumor growth relative to control in both xenografts. The
rate of tumor regression was similar in T738 xenografts treated withtriple therapy and trametinib plus pertuzumab underscoring the
importance HER2 heterodimer activation in this tumor.
In Vivo Molecular Response to EGFR, HER2, and
MEK1/2 Inhibition
To assess the signaling pathways impacted by the inhibitory
antibodies used in combination with trametinib, array platforms were
used to compare the changes in pEGFR and pHER2 and as well as
pERK, pAKT, c-Jun N-terminal kinase, phospho–c-Jun N-terminal
kinase (pJNK), and p70S6K. In all tumors, dual antibody therapy
produced a significant decrease in relative pEGFR compared to
untreated control tumors (Figure 5). As expected from the above
experiments, trametinib treatment alone yielded a more modest
decrease in relative level of pEGFR. In T608 and T738, combined
trametinib and antibody treatment sustained the decrease in pEGFR.
However, in T366, the relative pEGFR of triple therapy–treated
tumors was not significantly different from control values. This failure
to inhibit EGFR activation may have contributed to the modest
growth inhibition of T366 triple therapy–treated tumors relative to
tumors 608 and 738. In all tumors, pHER2 levels decreased upon
antibody therapy, consistent with the expected inhibition of EGFR
and HER2 signaling. Interestingly, in tumor 738, which harbors a
wild-type KRAS, we observed little inhibition of pHER2 with
trametinib treatment alone; however, it should be noted that the
overall pHER2 signals in this tumor were low.
Use of the array platforms to assess pERK, pAKT, pJNK, and
p70S6K revealed two response patterns. In the case of the mutant
KRAS T366 and T608, dual antibody treatment as well as trametinib
treatment yielded significant decreases in pERK1 and p70S6K. The
combination treatment with both antibodies and trametinib was also
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Figure 3. In vivo response of PDX tumors to trametinib and antibody treatment. (A, C, andE) In vivo responseof threedifferent establishedPDAC
tumors (100-500 mm3 before starting therapy) to treatment with vehicle control (black bar), trametinib (Tra), panitumumab (P), or trametinib plus
panitumumab (Tra + P) (treated mice, hatched bars). The number of mice in each treatment group is indicated in parentheses. An MRI was
obtained just before the start of treatment to establish an index tumor volume for each mouse. Subsequent interval MRI studies were used to
assess the change in tumor volumewhile on treatment (see FigureW2). To calculate the relative change in tumor volume (fold change) for each
tumor, the interval tumor volumesweredivided by the index tumor volumeand linear regressionwasused tomodel a line of best fit for the tumor
fold changedata plotted relative to time. The slopeof that line of best fit demonstrates the tumor growth rate for each treatment groupexpressed
as the fold change per week on treatment. Mean fold change per week plus the standard error of the mean are displayed for each treatment
group as bar graphs. Significance is denoted as *P b .05. Following the initial treatment period, a group of mice treated with trametinib was
maintained on trametinib. Mice in the panitumumab (P) group were switched to panitumumab plus trastuzumab (P + T) and mice in the
trametinib plus panitumumab (Tra + P) group were switched to combined treatment with panitumumab, trastuzumab, and trametinib
(Tra + P + T) for an additional 2 to 4weeks (openbars, FigureW2). (B,D, andF) RepresentativeMRI imagesof control and triple therapy–treated
(Tra + P + T) tumors obtained just before the onset of treatment (Start Rx) and at the conclusion of treatment just before sacrifice (EndRx). The
tumors are outlined and these images depict the axial slice with the largest cross-sectional area in each tumor.
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Figure 4. Comparison of in vivo response of PDX tumors to trametinib plus lapatinib versus trametinib plus antibody treatment. (A and B)
In vivo response of two different PDAC tumors to treatment with vehicle control, trametinib plus lapatinib (Tra + L), trametinib plus
pertuzumab (Tra + PZ), or trametinib plus panitumumab plus trastuzumab (Tra + P + T). Tumors were allowed to grow to a starting
volume of 100 to 500 mm3 before the onset of treatment. Mice were treated with vehicle control or drug therapy for 4 weeks (the number
of mice in each treatment group is indicated in parentheses). Initial tumor volume was assessed by MRI before the start of dosing and
subsequent weekly MRI assessments were carried out to calculate the change in relative tumor volume (see also Figure W3). The mean
relative tumor volume ± the standard error of the mean over time is plotted in line graph form for each treatment group. Linear regression
was used tomodel a line of best fit for the tumor fold change data plotted relative to time. The slope of that line of best fit that served as an
estimate of the tumor growth rate for each treatment group expressed as fold change per week on treatment was determined as
described in the Materials and Methods section. The mean fold change per week ± the standard error of the mean are displayed for each
treatment group as bar graphs. Significance is denoted as *P b .05.
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observations support the idea that EGFR and HER2 contribute
significantly to activation of pERK even in the setting of a mutant
KRAS. In contrast, dual antibody treatment or trametinib yielded
only modest effects on pAKT and pJNK, consistent with the earlier
noted possible feedback activation of the AKT pathway in response to
trametinib (Figure 5, A and B). In the case of the wild-type KRAS
T738, inhibition of pERK and p70S6K was most efficient in tumors
treated with both antibodies and trametinib and correlates with the
significant growth inhibition of this tumor observed upon triple
therapy. Interestingly, in this tumor, triple therapy blunted the
trametinib-induced increase in pAKT2 and pJNK, returning pAKT2
and pJNK to levels similar to those observed in control tumors
(Figure 5C).
Discussion
PDX tumor models in which surgically resected human pancreatic
adenocarcinomas are propagated orthotopically in the pancreas of
immunocompromised mice provide an ideal system to evaluate
combinatorial therapies in the context of a complex tumor
microenvironment. Not surprisingly, the effects of such therapies
can often differ from those observed in tissue culture models. In this
study, we have used the therapeutic antibodies panitumumab
(specific for EGFR) and trastuzumab (specific for HER2) to explore
the role of EGFR and HER2 signaling in the proliferation of PDX
tumors bearing mutant and wild-type KRAS alleles. We show that
dual anti-EGFR and anti-HER2 therapy significantly augmented the
growth inhibitory effects of the MEK1/2 inhibitor trametinib in three
different PDX tumors. While significant growth inhibition was
observed in both KRASmutant xenograft groups receiving trametinib
and dual antibody therapy (T366 and T608), tumor regression wasobserved in the KRAS wild-type xenografts (T738) treated in the
same manner. We observed that dual antibody therapy in
conjunction with trametinib was equally or more effective at
inhibiting tumor growth than trametinib plus lapatinib.
A possible role for trametinib as front-line therapy for pancreatic
cancer remains unclear. In the recent report of a phase 1b study of
trametinib in combination with gemcitabine for advanced solid
tumors, it was noted that of 10 patients with measurable pancreatic
cancer, three partial responses (30%) were documented. In a
randomized double-blind placebo-controlled trial of trametinib in
combination with gemcitabine for patients with untreated metastatic
adenocarcinoma, no improvement in overall survival, progression-free
survival, or response rate in patients was observed (discussed in [35]).
These studies underscore the difficulty of using single agents to
inhibit the growth of KRAS-driven cancers. The results reported
above provide additional evidence that concurrent blockade of EGFR,
HER2, and MEK1/2 pathways may lead to more effective pancreatic
tumor growth inhibition through a more complete inhibition of RAS
and phosphoinositide 3-kinase pathway signaling. Importantly,
combining monoclonal antibodies targeting EGFR and HER2 with
a MEK inhibitor provides an alternative and perhaps better tolerated
combination than lapatinib plus trametinib.
The importance of KRAS mutations in pancreas cancer is widely
accepted; in contrast, the contribution of cell-surface RTKs such as
EGFR and HER2 in pancreatic cancer progression is poorly
understood. One or more of the members of the EGF family of
receptors is expressed in a large proportion of pancreatic cancers
[36,37]. Further, studies using both mouse genetic models and
human pancreatic cancer cell lines suggest that development of
pancreatic adenocarcinomas is totally dependent on EGFR signaling
[38]. The EGFR inhibitor erlotinib is approved for use in metastatic
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Figure 5. Relative phosphorylation of RTKs andMAPKs in different PDX tumors. Extracts were prepared from PDX tumors following 4 to 6
weeks of in vivo treatment with vehicle control, panitumumab plus trastuzumab (P + T), trametinib (Tra), or triple therapy (Tra + P + T)
and analyzed on duplicate arrays. Bar graphs depict relative pEGFR (pan Y), pHER2 (pan Y), pERK1 (T202/Y204), pAKT2 (S474), pJNK-pan
(T183/Y185, T221/Y223), and p70S6K (T421/S424) levels in treated tumor 366 (A), tumor 608 (B), and tumor 738 (C) xenografts. Array
images from duplicate arrays were used to calculate the mean pixel density for each phospho-protein under each treatment condition.
Images were cropped and aligned from individual arrays exposed for the same period of time for ease of comparison with vertical bars
separating individual arrays. All phosphorylation values for each treatment group are presented normalized to control for each phospho-
protein assessed. Differences in relative phosphorylation were compared between groups with significance denoted as *P b .05. Image
acquisition and analysis were as described above in Figure 1. Figure W4 shows the complete array images.
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overall efficacy in clinical trials of unselected patients has been
minimal [39]. A recent report shows that overexpression of HER2
receptors is an independent factor for a worse patient outcome [18].
In preclinical studies, the combination of cetuximab (anti-EGFR
monoclonal antibody) and trastuzumab exhibited a synergistic
therapeutic effect on the growth of human pancreatic cancer celllines and xenografts [20]. In these studies, combination therapy
(cetuximab/trastuzumab) induced the stable down-regulation of
EGFR and HER2 and the downstream blockade of AKT
phosphorylation. In other studies, heterocombinations of monoclonal
antibodies against EGFR and HER2 exhibited enhanced efficacy
through a mechanism that enhanced receptor degradation [40]. These
studies provide additional evidence for the importance of EGFR and
570 EGFR, HER2, and MEK1/2 in pancreatic cancer Lindberg et al. Neoplasia Vol. 16, No. 7, 2014HER2 in pancreatic cancer and support the approach of combining
antibody therapy with targeted inhibition of signaling pathways.
As we report here, in vitro studies using cells cultured from KRAS
mutant PDX tumor 366 showed that pretreatment with panitumu-
mab or trastuzumab effectively inhibited the EGF-dependent
autophosphorylation of EGFR and HER2, respectively. Interestingly,
in the presence of trametinib, we observed a significant EGF-
dependent stimulation of HER2 autophosphorylation, consistent
with the feedback activation of this pathway. Indeed, in the presence
of trametinib, EGF stimulated the phosphorylation of AKT on S473,
and this phosphorylation was blunted by preincubation with
panitumumab, trastuzumab, or the combination of both antibodies.
These observations parallel our previous in vivo PDX studies [23] that
showed a similar increase in AKT phosphorylation following trametinib
treatment that was, in turn, blunted by lapatinib. We suggest that, at
least in T366 cells, the increase in AKT phosphorylation of S473 may
occur through the feedback activation of EGFR-HER2 heterodimers, a
process that is inhibited by treatment with panitumumab and
trastuzumab. It is important to note that in vivo treatment of T366
(as well as T608 and T738) with trametinib and both panitumumab
and trastuzumab effectively inhibited the phosphorylation of S473.
Paradoxically, in T366 cells, pretreatment with panitumumab,
trastuzumab, or the combination failed to inhibit EGF-stimulated
ERK phosphorylation. A recent report demonstrated that in head and
neck cancers, HER2 (ERBB2), EGFR (ERBB1), and the ligand
ephrinB1 (EFNB1) form a complex that enhances ERK signaling and
that the antibodies cetuximab (anti-EGFR) and trastuzumab failed to
block the EGF-stimulated signaling to ERK1/2 [41]. These studies
underscore the complexities of heterodimeric receptor signaling and
point out the need to understand more about the dynamics of EGFR
family signals in pancreatic cancers.
In the studies reported here and in our previous studies [23], we
observed that the KRAS wild-type T738 showed a notable sensitivity to
triple therapy and to combined trametinib-lapatinib therapy. A second
wild-type KRAS PDX tumor (T215) also showed increased sensitivity
to trametinib/dual antibody treatment (Figure W2). While it is unclear
what the oncogenic drivers are for these wild-type KRAS tumors, it
indicates that trametinib therapy may be more effective in such a
KRAS wild-type pancreatic cancer patient population.
In summary, the data presented here using PDX tumors support a
role for EGFR and HER2 in pancreatic cancer proliferation and
underscore the importance of therapeutic intervention in both the
KRAS-RAF-MEK-ERK and EGFR-HER2 pathways to achieve
maximal therapeutic efficacy in vivo. A clinical trial evaluating MEK
inhibitor plus panitumumab and trastuzumab or MEK inhibitor plus
pertuzumab should be considered in patients with pancreatic cancer.
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